ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2026
Lung Cancer Screening and Prevention: Beyond Conventional Strategies in a Rapidly Changing Global Milieu.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide despite advances in early detection and treatment. Furthermore, its epidemiology has undergone a profound transformation, necessitating a radical and comprehensive departure from traditional oncology frameworks. The historical paradigm, which focuses almost exclusively on tobacco smoking as the primary etiological driver, is increasingly inadequate to address the escalating global burden of lung cancer in never-smokers (LCINS). This epidemiologic shift is particularly evident in East Asian populations, where LCINS has transitioned from being a perceived outlier to becoming the dominant clinical phenotype, representing over 60% of all diagnosed cases in certain demographics especially in women. This comprehensive review integrates the exposome framework: a holistic methodology evaluating the cumulative and synergistic endogenous and environmental impact of air, water, and food pollutants across the human lifespan, with the practical and logistical implementation of precision screening. The addition of humanomics expands the concept of exposome to include societal structural inequalities. Rethinking lung cancer screening beyond a single imaging modality also requires a stronger focus on health equity. By synthesizing longitudinal data from the landmark TALENT study and integrating cutting-edge technologies such as artificial intelligence-driven risk prediction (Sybil) and advanced molecular triage using circulating tumor DNA, we advocate for a radical transition toward comprehensive computed tomography screening. This multisystem approach maximizes public health return on investment by simultaneously intercepting lung cancer, cardiovascular disease, and chronic respiratory illnesses at their earliest preclinical, asymptomatic, and most treatable stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.